Latest Neuroblastoma Stories
Perifosine demonstrated to be safe and tolerable, with early signs of clinical benefit in advanced refractory pediatric neuroblastoma patients QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
NEW YORK, June 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
CHICAGO, June 5 /PRNewswire/ -- Researchers from St.
Perifosine observed to be an effective novel agent in neuroblastoma cells in vitro and in vivo Phase 1 data of single agent perifosine as a treatment for recurrent solid tumors in pediatric patients, including neuroblastoma patients, to be presented at ASCO QUEBEC CITY, May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
NEW YORK, May 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of KRX-0401 (perifosine) in neuroblastoma tumor preclinical models.
A multicenter trial led by investigators from St Jude Children's Research Hospital achieved 71 percent survival after three yearsâ€”20 percent better than previously reported US rates.
QUEBEC CITY, April 20 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
NEW YORK, April 20 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 in Washington, DC.
New research in the FASEB Journal suggests that many types of childhood and adult cancers may be successfully treated with docosahexaenoic acid and its derivatives.
- Withering but not falling off, as a blossom that persists on a twig after flowering.